# Plasmacure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/plasmacure

- Industry: Medical Devices & Equipment
- Headquarters: Nijmegen, Netherlands
- Website: www.plasmacure.nl
- Total disclosed funding: $6.8M
- Latest round: Series A (Jun 8, 2025)
- Investors on record: 7

## About

Plasmacure BV, based in the Netherlands, develops innovative solutions for advanced wound healing utilizing patented cold plasma technology, particularly effective for chronic wounds such as diabetic foot ulcers.Plasmacure BV specializes in advanced wound healing solutions. Founded in 2013 in Nijmegen, Netherlands, the company has successfully conducted 2 deals to date. The firm raised EUR 6 million in Series A funding on June 8, 2025, with participation from several investors including Venture Medical, LLC, European Innovation Council, and Noaber Foundation. Bas Zeper serves as the CEO and is one of the founders.Plasmacure specializes in advanced wound healing solutions, primarily through its flagship product, PLASOMA. This patented cold plasma technology is designed to promote healing in chronic wounds, particularly those caused by diabetic foot ulcers. PLASOMA delivers bactericidal cold plasma directly to the wound site, significantly enhancing the healing process compared to conventional treatments. The service is primarily aimed at healthcare providers, including hospitals and clinics, that treat patients with chronic wounds. Plasmacure's products are marketed in various regions, with a focus on European countries, as well as selected markets in North America and Asia.Plasmacure generates revenue through direct sales of its PLASOMA technology to healthcare facilities, emphasizing a B2B transaction model. Medical institutions purchase the PLASOMA system, which involves an initial investment to integrate the technology into their wound care protocols. The firm positions itself as a leader in innovative wound care solutions, allowing healthcare providers to achieve remarkable cost savings and improved patient outcomes while managing chronic wound treatment.Following its recent EUR 6 million Series A funding raised in July 2025, Plasmacure BV plans to scale international market entry and expand the rollout of its cold plasma wound treatment technology for complex wounds. The company aims to introduce new products and enhance its presence in various geographic regions, targeting markets in Europe, North America, and Asia.

## Funding rounds

- Series A, Jun 8, 2025, $6.8M — Noaber Foundation, Oost NL, VGZ, European Innovation Council, Stichting Triade, Venture Medical, LLC
- Series A, Sep 18, 2018 — Oost NL, Next-Gen Ventures

## Investors

- Oost NL (https://capitalatlas.ai/funds/oost-nl) — Series A
- Next-Gen Ventures (https://capitalatlas.ai/funds/next-gen-ventures) — Series A
- Noaber Foundation — Series A
- VGZ — Series A
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series A
- Stichting Triade — Series A
- Venture Medical, LLC — Series A